Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis
Authors
Keywords
-
Journal
World Journal of Surgical Oncology
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-03-25
DOI
10.1186/s12957-022-02549-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunotherapy, Inflammation and Colorectal Cancer
- (2020) Charles Robert Lichtenstern et al. Cells
- A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion
- (2020) Juan Lyn Ang et al. EYE
- Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
- (2020) Shota Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
- (2020) Chongkai Wang et al. ONCOLOGIST
- Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer
- (2020) Eric X. Chen et al. JAMA Oncology
- Colorectal Cancer Immunotherapy: Options and Strategies
- (2020) Nor Adzimah Johdi et al. Frontiers in Immunology
- The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment
- (2020) Katie Hudson et al. Frontiers in Immunology
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy in colorectal cancer: rationale, challenges and potential
- (2019) Karuna Ganesh et al. Nature Reviews Gastroenterology & Hepatology
- Treatment sequencing in metastatic colorectal cancer
- (2019) D.P. Modest et al. EUROPEAN JOURNAL OF CANCER
- Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
- (2019) M D Hellmann et al. ANNALS OF ONCOLOGY
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- (2019) Cathy Eng et al. LANCET ONCOLOGY
- Vascularized pedicle iliac bone grafts as a hip-preserving surgery for femur head necrosis: a systematic review
- (2019) Fan Yang et al. Journal of Orthopaedic Surgery and Research
- Colorectal cancer
- (2019) Evelien Dekker et al. LANCET
- Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer
- (2019) Evrard et al. Cancers
- Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists
- (2018) Alexander Stein et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
- (2018) Anastasia Constantinidou et al. PHARMACOLOGY & THERAPEUTICS
- PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
- (2018) Ramón Cantero-Cid et al. BMC CANCER
- Current landscape of immune therapy in treatment of solid tumours, with future opportunities and challenges.
- (2018) N. A. Nixon et al. Current Oncology
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer
- (2017) Kristen K. Ciombor et al. ONCOLOGIST
- Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
- (2017) Bert H. O’Neil et al. PLoS One
- Microsatellite Instability as a Biomarker for PD-1 Blockade
- (2016) J. C. Dudley et al. CLINICAL CANCER RESEARCH
- A principal component analysis is conducted for a case series quality appraisal checklist
- (2016) Bing Guo et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- To Be Blunt: Are We Wasting Our Time? Emergency Department Thoracotomy Following Blunt Trauma: A Systematic Review and Meta-Analysis
- (2015) David Slessor et al. ANNALS OF EMERGENCY MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- The incidence of complications associated with lip and/or tongue piercings: a systematic review
- (2015) NL Hennequin-Hoenderdos et al. International Journal of Dental Hygiene
- Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
- (2013) Paul Lochhead et al. JNCI-Journal of the National Cancer Institute
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation